miDiagnostics’ Complete Blood Count (CBC) product in development analyzes various cellular components in the blood to diagnose and monitor a wide range of health issues.
The CBC product relies on lens-free imaging (LFI) technology, an advanced microscopy technique which creates holograms by passing light through a sample. It is particularly robust and compact due to the lack of lenses in the instrument, which means it has no service and maintenance requirements. These images are then processed using Artifical Intelligence expertise from NVIDIA, which harnesses machine learning to define and reconstruct images of individual cells.
The company plans to develop a wide range of clinical tests.
Differentiation of viral
versus bacterial infections
Also in development is a Molecular Diagnostic (MolDx) product, which is able to simultaneously analyze a sample for multiple pathogens. miDiagnostics’ approach enables more comprehensive syndromic testing, using ‘massive’ multiplex tests.
Samples are analyzed using a polymerase chain reaction method (qPCR) which can identify the presence of a virus, bacteria or other pathogens.
Its principal application will be for infectious diseases, providing a portable, lab-quality point-of-care solution.
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention”
“When it comes to making diagnostic decisions, it’s time to stop focusing on firefighting, it’s time to start investing in smoke detectors”